Hermès shares at a high: The stock market tips of the week

0
51

The “interpretation dispute” in things Novo Nordisk (NOVOB DC) has reached a new high: A larger Swiss financial institution has “warmed up” its recommendation with “Sell” within a month. I take it easy, because on Monday US stock exchange giant JP Morgan (JPM US) repeatedly left its advice at “Overweight”. With an investment performance of +206.5% over the last five years, you have a trump card in your portfolio with the CHF 241 billion stock. Could I, with a clear conscience, allow myself to be swayed into a sell recommendation if, according to my models, a record return on equity of 80.5% is promised for 2023? (Keep)

LEAVE A REPLY

Please enter your comment!
Please enter your name here